Protocol Details
Genotype -Phenotype Correlation of PKLR Variants with Pyruvate Kinase, 2,3-Diphosphglycerate and ATP Activities in Red Blood Cells of Patients with Sickle Cell Disease
This study is currently recruiting participants.
Summary
Number |
18-H-0146 |
Sponsoring Institute |
National Heart, Lung and Blood Institute (NHLBI) |
Recruitment Detail |
Type: Participants currently recruited/enrolled
Gender: Male & Female
Min Age: 18 Years
Max Age: 80 Years |
Referral Letter Required |
No |
Population Exclusion(s) |
Children |
Keywords |
ATP;
Trait;
GDP;
Genetics;
Natural History |
Recruitment Keyword(s) |
None |
Condition(s) |
Sickle Cell;
PKLR Variants;
Adenosine Triphosphate Activities |
Investigational Drug(s) |
None |
Investigational Device(s) |
None |
Intervention(s) |
None |
Supporting Site |
National Heart, Lung, and Blood Institute |
Background:
Some people with the same disorder on a genetic level have more complications than others. Researchers want to look for a link between the PKLR gene and sickle cell disease (SCD) symptoms. The PKLR gene helps create a protein, called pyruvate kinase that is essential in normal functioning of the red blood cell. Differences in the PKLR gene, called genetic variants, may cause some changes in the pyruvate kinase protein and other proteins, that can affect functioning of the red blood cell adding to the effect of SCD. Researchers can study these differences by looking at DNA (the material that determines inherited characteristics).
Objective:
To study how the PKLR gene affects sickle cell disease.
Eligibility:
Adults ages 18-80 of African descent. They may have sickle cell disease or not. They must not have had a transfusion recently or have a known deficiency of pyruvate kinase. They cannot be pregnant.
Design:
Participants will be screened with questions.
Participants will have blood drawn by needle in an arm vein. The blood will be genetically tested. Not much is known about how genes affect SCD, so the test results will not be shared with participants or their doctors.
Eligibility
INCLUSUION CRITERIA:
- Between 18 and 80 years of age
- African or of African descent
EXCLUSION CRITERIA:
- Self-reported history of blood transfusion within the last 8 weeks
- Known to have pyruvate kinase deficiency and be on AG348
-All volunteers will undergo the consent process under this protocol to allow for eligibility assessment. Once they have been consented to participate, they will undergo procedures per Protocol.
Citations:
Not Provided
Contacts:
Clinical Trials Number:
NCT03685721